Bots, editor, reviewer, Administrators
13,951
edits
Feed:All articles/Pretty: Difference between revisions
Jump to navigation
Jump to search
no edit summary
No edit summary |
No edit summary |
||
| Line 441: | Line 441: | ||
}, | }, | ||
{ | { | ||
"timestamp" : "2018- | "timestamp" : "2018-09-14T00:37:12Z", | ||
"briefDesignDescription" : "Chlorthalidone in HTN", | "briefDesignDescription" : "Chlorthalidone in HTN", | ||
"fulltexturl" : " | "fulltexturl" : "https://jamanetwork.com/journals/jama/fullarticle/vol/288/pg/2981", | ||
"pageid" : 171, | "pageid" : 171, | ||
"pdfurl" : | "pdfurl" : null, | ||
"trainingLevel" : "Student", | "trainingLevel" : "Student", | ||
"citation" : "Wright JT, <i>et al</i>. \"Major Outcomes in High-Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs. Diuretic\". <i>Journal of the American Medical Association</i>. 2002. 288(23):2981-2997.", | "citation" : "Wright JT, <i>et al</i>. \"Major Outcomes in High-Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs. Diuretic\". <i>Journal of the American Medical Association</i>. 2002. 288(23):2981-2997.", | ||
"subspecialties" : "Nephrology;Cardiology", | "subspecialties" : "Nephrology;Cardiology", | ||
"expansion" : " | "expansion" : "Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial", | ||
"statusUsableDate" : "2012-03-01", | "statusUsableDate" : "2012-03-01", | ||
"briefResultsDescription" : "Chlorthalidone performs similarly to lisinopril and amlodipine", | "briefResultsDescription" : "Chlorthalidone performs similarly to lisinopril and amlodipine", | ||
| Line 3,783: | Line 3,783: | ||
"title" : "Rivaroxaban for thromboprophylaxis in acutely ill medical patients", | "title" : "Rivaroxaban for thromboprophylaxis in acutely ill medical patients", | ||
"pmid" : "23388003" | "pmid" : "23388003" | ||
}, | |||
{ | |||
"timestamp" : "2018-09-14T00:06:56Z", | |||
"briefDesignDescription" : "Rivaroxaban VTE ppx after medical admission", | |||
"fulltexturl" : "https://www.nejm.org/doi/full/10.1056/NEJMoa1805090", | |||
"pageid" : 3699, | |||
"pdfurl" : "https://www.nejm.org/doi/pdf/10.1056/NEJMoa1805090", | |||
"trainingLevel" : "Resident", | |||
"citation" : "Spyropoulos AC, <i>et al</i>. \"Rivaroxaban for Thromboprophylaxis after Hospitalization for Medical Illness\". <i>The New England Journal of Medicine</i>. 2018. e-published 2018-08-26:1-10.", | |||
"subspecialties" : "Hematology;Cardiology", | |||
"expansion" : "Medically Ill Patient Assessment of Rivaroxaban versus Placebo in Reducing Post-Discharge Venous Thrombo-Embolism Risk", | |||
"statusUsableDate" : "2018-09-13", | |||
"briefResultsDescription" : "Rivaroxaban does not prevent VTE in medically ill patients", | |||
"published" : "2017-08-27", | |||
"pageName" : "MARINER", | |||
"diseases" : "Venous Thromboembolism;Deep Vein Thrombosis;Pulmonary Embolism", | |||
"abbreviation" : "MARINER", | |||
"title" : "Rivaroxaban for Thromboprophylaxis after Hospitalization for Medical Illness", | |||
"pmid" : "30145946" | |||
}, | }, | ||
{ | { | ||